INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 5.14
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.81

26 Sep
2025

-0.040

OPEN

$2.83

-1.40%

HIGH

$2.83

636,794

LOW

$2.78

TARGET
$3.35 19.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.5 13.2 xxx
DPS (cps) xxx 6.5 8.7 xxx
EPS Growth xxx N/A 100.0% xxx
DPS Growth xxx 12.1% 33.1% xxx
PE Ratio xxx N/A 21.2 xxx
Dividend Yield xxx N/A 3.1% xxx
Div Pay Ratio(%) xxx 427.6% 65.4% xxx

Dividend yield today if purchased 3 years ago: 2.41%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 2.31

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.5
DPS All xxxxxxxxxxxxxxx6.5
Sales/Revenue xxxxxxxxxxxxxxx627.2 M
Book Value Per Share xxxxxxxxxxxxxxx186.2
Net Operating Cash Flow xxxxxxxxxxxxxxx73.8 M
Net Profit Margin xxxxxxxxxxxxxxx0.75 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx0.94 %
Return on Invested Capital xxxxxxxxxxxxxxx0.49 %
Return on Assets xxxxxxxxxxxxxxx0.43 %
Return on Equity xxxxxxxxxxxxxxx0.94 %
Return on Total Capital xxxxxxxxxxxxxxx5.90 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-1.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx20 M
Long Term Debt xxxxxxxxxxxxxxx565 M
Total Debt xxxxxxxxxxxxxxx585 M
Goodwill - Gross xxxxxxxxxxxxxxx802 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx52 M
Price To Book Value xxxxxxxxxxxxxxx1.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx59.8 M
Capex % of Sales xxxxxxxxxxxxxxx9.53 %
Cost of Goods Sold xxxxxxxxxxxxxxx489 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx82 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

27/08/2025

1

Buy

$3.30

17.44%

Integral Diagnostics announced a slight 1% earnings (EBITDA) beat against Ord Minnett and consensus forecasts.

Australian market share rose in 2H25 after underperforming in FY24–1H25, the analyst highlights. The 2H25 group earnings (EBITDA) margin rose 110bps to 21.4%.

The FY26 outlook remains positive, with like-for-like sales for July revenue growth of 7% on the prior year and an updated synergy target for Capitol of $14m versus $10m previously.

Target price rises to $3.30 from $3.00. No change in Buy rating. Ord Minnett lowers its FY26 EPS forecast by -3% and raises FY27 by 2%.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 9.00 cents and EPS of 12.60 cents.
Ord Minnett forecasts a full year FY27 dividend of 10.60 cents and EPS of 15.10 cents.

Citi

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

3

xxxxxxxxx xx xxxxxx xxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

03/09/2025

1

Buy

$3.41

21.35%

Integral Diagnostics reported better-than-expected FY25 earnings, with net profit after tax assisted by lower depreciation, according to Jarden.

The outlook for FY26 relies on MRI deregulation, the National Lung Screening Program, the GP Bulk Billing program, as well as synergy capture and other factors, including slowing capex to -$45m-$55m from around -$65m.

Positively, labour costs have slowed into FY26, but any impacts will take time, commentary highlights, as will the spread of MRI deregulation benefits.

Jarden lowers its EPS forecasts by -7.3% for FY26 and -5.4% for FY27. Buy retained. Target falls to $3.41 from $3.45.

FORECAST
Jarden forecasts a full year FY26 dividend of 9.30 cents and EPS of 14.20 cents.
Jarden forecasts a full year FY27 dividend of 12.00 cents and EPS of 18.30 cents.

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IDX STOCK CHART

FNArena News on IDX

1
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 05-09-25

Sep 05 2025 - Weekly Reports
3
Rudi’s View: Catalyst Metals, Dexus, Neuren, Stockland, ResMed & More

Sep 04 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 01, 2025

Sep 01 2025 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps